Title |
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients
|
---|---|
Published in |
Clinical Epigenetics, April 2016
|
DOI | 10.1186/s13148-016-0203-8 |
Pubmed ID | |
Authors |
Duo Chen, Xianyu Wen, Young Seok Song, Ye-Young Rhee, Tae Hun Lee, Nam Yun Cho, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang |
Abstract |
Low methylation status of LINE-1 in tumors is associated with poor survival in patients with colon cancer. Eastern Cooperative Oncology Group performance status (ECOG-PS) is a method to assess the functional status of a patient. We retrospectively evaluated the relationship between ECOG-PS and LINE-1 methylation in colorectal cancers (CRCs) and their prognostic impact in CRC or colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX). LINE-1 methylation and microsatellite instability were analyzed in stage III or high-risk stage II CRCs (n = 336). LINE-1 methylation levels were correlated with clinicopathological features, including PS and recurrence-free survival (RFS). The association between the tumoral LINE-1 methylation level and PS was observed (OR = 2.56, P < 0.001). Differences in LINE-1 methylation levels in cancer tissue between the PS 0 and 1 groups were significant in patients older than 60 years (P = 0.001), the overweight body mass index group (P = 0.005), and the stage III disease group (P = 0.008). Prognostic significances of LINE-1 methylation status or combined PS and LINE-1 methylation statuses were identified in stage III colon cancers, not in stage III and high-risk stage II CRCs. Low LINE-1 methylation status was closely associated with a shorter RFS time. The difference between PS(0)/LINE-1(high) and PS(≥1)/LINE-1(low) was significant, which suggests that colon cancer patients with concurrent PS(≥1)/LINE-1 (low) have a higher recurrence rate. PS was associated with LINE-1 methylation in CRC tissue. LINE-1 methylation was associated with RFS in stage III colon cancer patients who were treated with adjuvant FOLFOX chemotherapy. Combined PS and LINE-1 methylation status might serve as a useful predictor of cancer recurrence. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 28% |
Researcher | 5 | 20% |
Student > Bachelor | 4 | 16% |
Student > Master | 4 | 16% |
Lecturer > Senior Lecturer | 1 | 4% |
Other | 1 | 4% |
Unknown | 3 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 32% |
Biochemistry, Genetics and Molecular Biology | 7 | 28% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Other | 2 | 8% |
Unknown | 5 | 20% |